245 related articles for article (PubMed ID: 22654433)
41. Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients.
Koh J; Nam SK; Lee YW; Kim JW; Lee KW; Ock CY; Oh DY; Ahn SH; Kim HH; Kang KW; Kim WH; Lee HY; Lee HS
Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31779184
[TBL] [Abstract][Full Text] [Related]
42. Differential expression of HER2 and downstream proteins in prediction of advanced tumor phenotypes and overall survival of patients with Epstein-Barr virus-positive vs. negative gastric cancers.
Zhang YW; He D; Tan C; Dong M; Zhou L; Shao CK
Pathol Res Pract; 2019 Nov; 215(11):152675. PubMed ID: 31594682
[TBL] [Abstract][Full Text] [Related]
43. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.
Terashima M; Kitada K; Ochiai A; Ichikawa W; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M;
Clin Cancer Res; 2012 Nov; 18(21):5992-6000. PubMed ID: 22977193
[TBL] [Abstract][Full Text] [Related]
44. High expression of miR-16 and miR-451 predicating better prognosis in patients with gastric cancer.
Ren C; Chen H; Han C; Fu D; Wang D; Shen M
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2489-2496. PubMed ID: 27605261
[TBL] [Abstract][Full Text] [Related]
45. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
[TBL] [Abstract][Full Text] [Related]
46. Prevalence of HER2 Positivity and Its Clinicopathological Correlation in Locally Advanced/Metastatic Gastric Cancer Patients in Malaysia.
Rajadurai P; Fatt HK; Ching FY
J Gastrointest Cancer; 2018 Jun; 49(2):150-157. PubMed ID: 28124769
[TBL] [Abstract][Full Text] [Related]
47. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
[TBL] [Abstract][Full Text] [Related]
48. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.
Grabsch H; Sivakumar S; Gray S; Gabbert HE; Müller W
Cell Oncol; 2010; 32(1-2):57-65. PubMed ID: 20208134
[TBL] [Abstract][Full Text] [Related]
49. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
[TBL] [Abstract][Full Text] [Related]
50. The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer.
Duan XF; Dong NN; Zhang T; Li Q
Int J Clin Oncol; 2013 Feb; 18(1):26-32. PubMed ID: 22041927
[TBL] [Abstract][Full Text] [Related]
51. Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients.
Cao GD; Chen K; Chen B; Xiong MM
BMC Cancer; 2017 Dec; 17(1):841. PubMed ID: 29233126
[TBL] [Abstract][Full Text] [Related]
52. Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics.
Lee JS; Kim SH; Im SA; Kim MA; Han JK
Korean J Radiol; 2017; 18(5):809-820. PubMed ID: 28860898
[TBL] [Abstract][Full Text] [Related]
53. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.
Shun CT; Wu MS; Lin JT; Chen SY; Wang HP; Lee WJ; Wang TH; Chuang SM
Hepatogastroenterology; 1997; 44(14):604-9. PubMed ID: 9164544
[TBL] [Abstract][Full Text] [Related]
54. Low frequency of HER2 amplification and overexpression in early onset gastric cancer.
Moelans CB; Milne AN; Morsink FH; Offerhaus GJ; van Diest PJ
Cell Oncol (Dordr); 2011 Apr; 34(2):89-95. PubMed ID: 21394646
[TBL] [Abstract][Full Text] [Related]
55. Metabolic Signature on 18F-FDG PET/CT, HER2 Status, and Survival in Gastric Adenocarcinomas.
Celli R; Colunga M; Patel N; Djekidel M; Jain D
J Nucl Med Technol; 2016 Dec; 44(4):234-238. PubMed ID: 27789750
[TBL] [Abstract][Full Text] [Related]
56. Effect of EGFR and p-AKT Overexpression on Chromosomal Instability in Gastric Cancer.
Hisamatsu Y; Oki E; Otsu H; Ando K; Saeki H; Tokunaga E; Aishima S; Morita M; Oda Y; Maehara Y
Ann Surg Oncol; 2016 Jun; 23(6):1986-92. PubMed ID: 26847684
[TBL] [Abstract][Full Text] [Related]
57. HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran.
Feizy A; Karami A; Eghdamzamiri R; Moghimi M; Taheri H; Mousavinasab N
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1721-1725. PubMed ID: 29938472
[TBL] [Abstract][Full Text] [Related]
58. Prognostic value of hypoxia-inducible factor-1 alpha and prolyl 4-hydroxylase beta polypeptide overexpression in gastric cancer.
Zhang J; Wu Y; Lin YH; Guo S; Ning PF; Zheng ZC; Wang Y; Zhao Y
World J Gastroenterol; 2018 Jun; 24(22):2381-2391. PubMed ID: 29904245
[TBL] [Abstract][Full Text] [Related]
59. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
[TBL] [Abstract][Full Text] [Related]
60. HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer.
Han S; Park S; An J; Yang JY; Chung JW; Kim YJ; Kim KO; Park DK; Kwon KA; Lee WK; Nam S; Kim JH
Sci Rep; 2020 Mar; 10(1):5270. PubMed ID: 32210254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
